Tag:
Dalbavancin
Latest Headlines
Latest Headlines
Pfizer's thin-skinned pipeline
Dalbavancin--the once-weekly skin antibiotic that Pfizer acquired as part of its 2005 $1.9 billion Vicuron Pharmaceuticals buyout--will not be going before the FDA anytime soon. Pfizer announced
